Gainers
-
Novocure Ltd (NASDAQ: NVCR) rose 40.1 percent to
$11.35 in pre-market trading after the company disclosed that the two-year survival rate for GBM Patients increased from 30% to
43% for patients treated with Optune + temozolomide versus temozolomide alone at the AACR 2017.
-
Steadymed Ltd (NASDAQ: STDY) shares rose 31
percent to $7.60 in pre-market trading. Cardiome's partner SteadyMed received a favorable ruling in USPTO Inter Partes Review
in validity of U.S. Patent No. 8,497,393.
-
Cellect Biotechnology Ltd. (NASDAQ: APOP) rose
15.6 percent to $9.94 in pre-market trading after the company reported an European patent grant.
-
Dynavax Technologies Corporation (NASDAQ: DVAX)
rose 15.1 percent to $6.85 in pre-market trading after the company disclosed that the PDUFA date for HEPLISAV-B will remain
unchanged.
-
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX)
shares rose 9.6 percent to $9.21 in pre-market trading after the company reported that Mundipharma has received approval for
Mundesine in Japan.
-
BiondVax Pharmaceuticals Ltd (ADR) (NASDAQ: BVXV)
rose 9.5 percent to $6.35 in pre-market trading after declining 6.90 percent on Friday.
-
Eleven Biotherapeutics Inc (NASDAQ: EBIO) rose
9.1 percent to $2.40 in pre-market trading. Eleven Biotherapeutics presented new preclinical data supporting potential of the
company's locally and systematically-administered drug candidates at the AACR 2017.
-
Infinity Pharmaceuticals Inc. (NASDAQ: INFI) rose
8.4 percent to $3.50 in pre-market trading. Infinity Pharmaceuticals presented updated Phase 1 data for IPI-549 at the AACR
2017.
-
Matinas BioPharma Holdings Inc (NYSE: MTNB) rose
8.3 percent to $3.00 in pre-market trading. Matinas BioPharma reported a FY16 loss of $0.21 per share.
-
Medigus Ltd. (NASDAQ: MDGS) shares rose 7.1
percent to $3.30 in pre-market trading after dropping 3.14 percent on Friday.
-
AerCap Holdings N.V. (NYSE: AER) rose 6.3 percent to
$48.86 in pre-market trading after gaining 0.13 percent on Friday.
-
Kite Pharma Inc (NASDAQ: KITE) rose 5.8 percent
to $83.01 in pre-market trading. Kite presented ongoing response rate in plenary session from its pivotal CAR-T trial of
Axicabtagene Ciloleucel in patients with aggressive non-hodgkin lymphoma at AACR 2017.
-
Nabors Industries Ltd. (NYSE: NBR) shares rose 5.1
percent to $13.74 in pre-market trading after gaining 0.15 percent on Friday.
-
Syneron Medical Ltd. (NASDAQ: ELOS) shares rose
4.7 percent to $11.05 in pre-market trading. Syneron Candela agreed to be acquired by funds advised by Apax Partners for $11
per share in cash,
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.
Losers
-
United Therapeutics Corporation (NASDAQ: UTHR)
dropped 9.1 percent to $123.00 in pre-market trading after the company disclosed that the US launch of RemoSynch will be
delayed due to regulatory delays.
-
Acorda Therapeutics Inc (NASDAQ: ACOR) shares
fell 5 percent to $19.95 in the pre-market trading session after declining 21.50 percent on Friday.
-
Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) shares
fell 4.4 percent to $3.25 in pre-market trading after climbing 25.93 percent on Friday.
-
Conatus Pharmaceuticals Inc (NASDAQ: CNAT) fell 3
percent to $5.60 in pre-market trading after declining 2.53 percent on Friday.
-
DRDGOLD Ltd. (ADR) (NYSE: DRD) fell 2.7 percent to
$4.78 in pre-market trading after rising 1.87 percent on Friday.
-
DBV Technologies SA - ADR (NASDAQ: DBVT) shares
fell 2.4 percent to $34.39 in pre-market trading after gaining 1.00 percent on Friday.
-
Accenture Plc (NYSE: ACN) fell 2.2 percent to
$117.22 in pre-market trading. Goldman Sachs downgraded Accenture from Neutral to Sell and lowered the price target from
$125.00 to $110.00.
-
Deutsche Bank AG (USA) (NYSE: DB) fell 2.1 percent to
$16.81 in pre-market trading after dropping 0.58 percent on Friday.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.